Level C· Early human research exploring benefitsProspective StudyPubMed

Sarcopenia and fat loss from serial CT predict survival in multiple myeloma patients undergoing stem cell transplantation.

Kylies J., Brauneck E., Priemel M., Kylies D., Weisel K., Leonhardt LG.

Prospective Study on Back & Spine, published in World J Surg Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
World J Surg Oncol (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40963145
DOI
10.1186/s12957-025-04007-6

Abstract (original English)

Frailty and sarcopenia are associated with adverse outcomes in multiple myeloma (MM), but their longitudinal changes and clinical relevance remain unclear. This study evaluated the longitudinal changes in body composition parameters derived from computed tomography (CT) scans and their association with survival and functional decline in MM patients undergoing autologous stem cell transplantation (ASCT). We analyzed 49 MM patients who underwent three sequential CT scans between 2009 and 2024. CT-based body composition parameters-skeletal muscle index (SMI), paraspinal muscle index (PSMI), psoas muscle index (PMI), skeletal muscle density (SMD), and visceral adipose tissue (VAT)-were measured at the L3 level. Changes in these parameters were assessed over the disease course, and their impact on survival and functional outcome was evaluated using Cox proportional hazards regression models and Kaplan-Meier survival analyses. CT morphometric body composition parameters declined significantly over time in both sexes. In males, SMI decreased from 48.6 ± 7.1 to 38.4 ± 8.1 cm 2 /m 2 (-21%, p < 0.0001); in females, from 36.6 ± 7.8 to 26.9 ± 4.7 cm 2 /m 2 (-26%, p < 0.0001). VAT declined from 115.9 ± 9.1 to 84.9 ± 9.7 cm 2 in males (-27%, p < 0.0001) and from 63.5 ± 7.1 to 42.1 ± 7.7 cm 2 in females (-34%, p < 0.0001). Patients < 55 years showed comparable declines (e.g., male SMI -21%, V

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansFemaleMaleSarcopeniaMultiple MyelomaMiddle AgedTomography, X-Ray ComputedBody CompositionPrognosisSurvival Rate

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research